Specific nucleic acid aptamers neutralize c-Met signaling pathways, resolving the lack of effective binding substances for cancer diagnosis and treatment.
Fully human monoclonal antibodies against OX40 reduce immunogenicity while enhancing T cell proliferation and cytokine production.
Combining methotrexate with simvastatin reduces severe neurotoxicity and myelosuppression while maintaining therapeutic efficacy in osteosarcoma treatment.
Using cell lines expressing functional large T antigen without small T antigen enables scalable production of safe, non-replicating viral vectors.
Optimized monoclonal antibodies bind CTLA-4 with superior affinity, resolving insufficient blocking activity in existing therapies.
A pharmaceutical composition containing pinitol or D-chiro-inositol alleviates premenstrual syndrome symptoms.
A polymer matrix device combines methyl salicylate with essential oils to accelerate transdermal transport of the active agent.
A biotinylation protocol isolates the Plg-RKT membrane protein using affinity chromatography and MudPIT analysis.
Humanized CD3 antibodies form multispecific complexes that activate T cells to recognize and kill cancer cells.
Guava leaf extract elevates blood adiponectin levels, addressing the lack of safe long-term therapeutic substances.
Composite polymer matrices stabilize high-concentration bio-fermented sodium hyaluronate, resolving viscosity and degradation bottlenecks.
Targeted inhibitors reduce toxicity while eliminating tumorigenic potential in aggressive basal-like cancers.
Amino acid substitutions in the antibody Fc region enhance FcRn receptor binding affinity.
A cannabis and avocado soybean unsaponifiables composition reduces inflammatory responses through synergistic modulation of cytokine production.